China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape
Policy / Regulatory

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

China's National Health Commission (NHC) issued the Working Procedures for Formulating the Rare Disease Catalogue (2026 Edition) on 4 Nov 2026, a policy revision designed to strengthen rare disease management,…

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Huadong Medicine's Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults
CompanyDrug

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Pfizer's Hympavzi Wins NMPA Approval for a New Indication in China – World's First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors
CompanyDrug

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Hybio Pharmaceutical's Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH
CompanyDrug

Hybio Pharmaceutical’s Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

GenSci's Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis
CompanyDrug

GenSci’s Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

NMPA Grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

NMPA Grants Priority Review to Hengrui's Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for a new indication of Trastuzumab rezetecan, with priority review granted. The application seeks approval for…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program
CompanyDeals

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets
CompanyDeals

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India
CompanyDeals

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau
CompanyDeals

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories
CompanyDeals

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Synmosa Biopharma (TPE: 4114) announced that it has signed an exclusive licensing, supply, and commercialization agreement with Nxera Pharma Japan, a subsidiary of Japan's Nxera Pharma, for the insomnia therapy…

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones
CompanyDeals

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion
CompanyDeals

AstraZeneca Proposes ~US$10 Billion Acquisition of Obesity Drugmaker Rhythm Pharmaceuticals – Deal to Be Pursued Through Rare Disease Unit Alexion

Eisai and Meituan Healthcare Sign Instant Retail Partnership at CIIE – Dayvigo 14‑Tablet Pack Powers "Order at Night, Delivered Nearby" Sleep Health Ecosystem
CompanyDeals

Eisai and Meituan Healthcare Sign Instant Retail Partnership at CIIE – Dayvigo 14‑Tablet Pack Powers “Order at Night, Delivered Nearby” Sleep Health Ecosystem

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CompanyDeals

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Policy / Regulatory

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions
Policy / Regulatory

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

More News

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million
Company

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes
Company

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion
Company

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion

Immunochina's IM19 Wins NMPA Approval – First Fully In‑House CD19 CAR‑T Cell Therapy for Relapsed or Refractory Large B‑Cell Lymphoma in China
CompanyDrug

Immunochina’s IM19 Wins NMPA Approval – First Fully In‑House CD19 CAR‑T Cell Therapy for Relapsed or Refractory Large B‑Cell Lymphoma in China

Bio‑Thera's BAT2506 Wins NMPA Approval – First Golimumab Biosimilar in China for Rheumatoid Arthritis and Ankylosing Spondylitis
CompanyDrug

Bio‑Thera’s BAT2506 Wins NMPA Approval – First Golimumab Biosimilar in China for Rheumatoid Arthritis and Ankylosing Spondylitis

Fosun Pharma Advances Two Pipeline Programs – FXS6837 Enters Phase III for PNH in China as IL1RAP Antibody HLX109 Clears Phase I in Australia
CompanyDrug

Fosun Pharma Advances Two Pipeline Programs – FXS6837 Enters Phase III for PNH in China as IL1RAP Antibody HLX109 Clears Phase I in Australia

Johnson & Johnson's Rybrevant Faspro Wins FDA Accelerated Approval – First Dual‑Target EGFR–MET Therapy for Pretreated HNSCC
CompanyDrug

Johnson & Johnson’s Rybrevant Faspro Wins FDA Accelerated Approval – First Dual‑Target EGFR–MET Therapy for Pretreated HNSCC

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform
CompanyDeals

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Show More